Palladyne (NASDAQ:PDYN) executed a previously announced contract from the Air Force Research Laboratory (AFRL) to develop technology that enables autonomous defense systems to operate as a coordinated network.
Zoetis (NYSE:ZTS) announced that the European Commission (EC) granted marketing authorization for Poulvac Procerta HVT-ND, a recombinant vector vaccine designed to protect chickens against Newcastle disease (ND) and Marek’s disease.
Gilat Satellite Networks (NASDAQ:GILT) announced that its Gilat DataPath subsidiary received approximately $11 million in orders from the U.S. Department of War for field services and customized SATCOM terminals.
UniTek Global Services acquired Concurrent Utility Services, a specialty infrastructure services company focused on power grid modernization and connectivity, to expand its Power Services Division.
Miami International Holdings (NYSE:MIAX) reported June 2026 trading metrics showing higher activity across its options exchanges, with U.S. multi-list options year-to-date average daily volume reaching 10.9 million contracts.
The Trump administration's proposed Strategic Bitcoin Reserve has encountered an internal obstacle, with two federal departments competing for oversight of the initiative amid unresolved questions over legal authority, according to a Bloomberg report.
Compass Pathways (NASDAQ:CMPS) announced Phase 3 clinical trial results demonstrating that its proprietary synthetic psilocybin compound, COMP360, provides durable therapeutic relief for treatment-resistant depression.
Equifax (NYSE:EFX) agreed to acquire Círculo de Crédito, a Mexico-based credit bureau, in a transaction valued at an enterprise value of $750 million and a purchase price of $825 million.
Getty Images (NYSE:GETY) officially terminated its proposed corporate merger agreement with Shutterstock (NYSE:SSTK) following antitrust regulatory complications.
Alterity Therapeutics (NASDAQ:ATHE) announced it received official End-of-Phase-2 meeting minutes from the FDA confirming the registrational design pathways for its neurodegenerative drug candidate ATH434.
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift
